Outlook Therapeutics reports Q3 FY2026 results; FDA-approved LYTENAVA launch planned by end of 2026

Outlook Therapeutics, Inc.

Net loss $20.3M ($0.15/share) vs $20.2M ($0.55/share) YoY; adjusted net loss $10.9M ($0.09/share) vs $15.8M ($0.44/share).
Cash $11.2M at June 30, 2026; subsequent public offering raised ~$51.1M net from 55.6M shares at $0.99.
FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD; U.S. launch planned before end of calendar 2026.
Management sees potential to exceed $500M annual U.S. sales by 2030; HCPCS code application by Oct 1, 2026.
European expansion: Germany, Austria, UK; Netherlands launch later 2026; Switzerland partner Mediconsult launch 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.